Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA – ANNALS OF ONCOLOGY

Felip, E; Cho, BC; Gutiérrez, ; Alip, A; Besse, B; Lu, S; Spira, AI; Girard, N; Califano, R; Gadgeel, SM; Yang, JCH; Yamamoto, S; Azuma, K; Kim, YJ; Lee, KH; Danchaivijitr, P; Ferreira, CG; Cheng, Y; Sendur, MAN; Chang, GC; Wang, CC; Prabhash, K; Shinno, Y;...